Pfizer (PFE) Long-Term Debt Issuances (2009 - 2025)

Pfizer (PFE) reported Long-Term Debt Issuances of $6.0 billion for Q4 2025, up 500.9% quarter-over-quarter from $997.0 million in Q4 2021.

Pfizer (PFE) Long-Term Debt Issuances (2009 - 2025) Analysis & Trends

Pfizer (PFE) has 12 years of Long-Term Debt Issuances data on file, last reported at $6.0 billion in Q4 2025.

Long-Term Debt Issuances for Q4 2025 came in at $6.0 billion, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.0 billion (changed N/A YoY), and the FY2025 annual result was $9.7 billion, changed N/A from the prior year.
Long-Term Debt Issuances advanced to $6.0 billion in Q4 2025 per PFE's latest filing, from $997.0 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $6.0 billion in Q4 2025 and troughed at $997.0 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	-
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	-
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	7.99 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	-
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	3.96 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	-
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	-
10	Novartis Ag	108.28 Bn	107.60 Bn	-	-

Download Data